期刊文献+

经导管植入式主动脉人工心脏瓣膜临床试验初步建议

Considerations on Clinical Study of Transcatheter Aortic Valve Implantation
下载PDF
导出
摘要 用于治疗有症状的重度主动脉瓣狭窄的经导管植入式主动脉人工心脏瓣膜的研发日益增多,但并未有规范性临床试验指导意见,缺少安全性和有效性评价的统一原则,为了更好地引导研究者完成上市前临床试验研究,通过结合该类产品已完成的临床试验研究情况、心脏病治疗指南及国内心血管内科、心血管外科和临床统计学专家的意见,总结了目前对于该类产品临床试验的初步建议。在中国境内开展临床试验时,建议首先完成可行性研究;确证性研究按照产品应用人群风险收益分析,分别对开展安全性和有效性评价,建议优先选择不适合常规外科手术有症状的重度主动脉瓣狭窄患者作为受试人群。 Transcatheter aortic valve implantation for the patients suffering from severe aortic stenosis has emerged as a promising technique alternative to conventional surgical aortic valve replacement, the guidances of clinical study to evaluate the safety and efficacy of the products have not been drafted as so far. The recommendations which were drafted according to the existing clinical data and guideline for valvular heart disease and expert advice were introduced in the article in order to provide a guidance to manufacturers. Feasibility study to see if a larger pivotal study is practical and to refine the study protocol for the pivotal study was recommended firstly, the hypothesis of pivotal study was built in accordance with benefit-risk analysis, the aortic stenosis patients who cannot undergo surgery was preferen- tially treated in clinical trial.
出处 《中国药物警戒》 2014年第10期628-631,共4页 Chinese Journal of Pharmacovigilance
关键词 经导管植入式主动脉人工心脏瓣膜 临床试验 可行性研究 确证性研究 transcatheter aortic valve implantation clinical trial feasibility study pivotal study
  • 相关文献

参考文献12

  • 1Leon M B, Smith C R, Mack M, et al. Transcatheter aortic-valveimplantation for aortic stenosis in patients who cannot undergosurgery[J]. N Engl J Med, 2010,363(17): 1597-1607.
  • 2Andersen H R, Knudsen L L,Hasenkam J M. Transluminal im-plan-tation of artificial heart valves: Description of a new expand-able aortic valve and initial results with implantation by cathetertechnique in closed chest pigs[J]. Eur Heart J, 1992,13(5): 704-708.
  • 3Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcathetersis: first human case description[J]. Circulation, 2002,106(24): 3006-3008.
  • 4Grube E, Laborde J C, Gerckens U, et al. Percutaneous implanta-tion of the CoreValve self-expanding valve prosthesis in high-riskpatients with aortic valve disease: the Siegburg first-in-man study [J].Circulation, 2006, 114(15): 1616-1624.
  • 5FDA. The Edwards SAPIEN THV transcatheter heart valve systemfor patients with severe aortic stenosis who are not candidates forconventional open-heart aortic valve replacement surgery [EB/OL].(2011-07)[2014-06-20]. httpy/wwwfdagov/downloads/advisoryco-mmittees/committeesmeetingmaterials/medicaldevices/medicaldev-icesadvisoiycomimttee/circuIatoiysystemdevicespanel/ucm262935. pdf.
  • 6FDA. Summary of safety and effectiveness data [EB/OL]. (2014-01)[2014-06-20]. http: //www ? accessdata.fda. gov/cdrh_docs/pdfl3/P130021b.pdf.
  • 7Boston Scientific announces first commercial implants of the Lotusvalve system in Europe [EB/OL].(2013-11—15)[2014-06—20].http'7/news.bostonscientific.com/2013-ll-15-Boston—Scientific-An-nounces—First-Commercial-Impknts-Of—T-he-Lotus—Valve-System-in-Europe.
  • 8Vahanian A, Alfieri 0,Andreotti F, et al. Guidelines on the man-agement of valvular heart disease (version 2012)[J]. Eur Heart J, 2012,33(19): 2451-2496.
  • 9Leon M B, Piazza N, Nikolsky E, et al. Standardized endpoint defini-tions for transcatheter aortic valve implantation clinical trials: aconsensus report from the Valve Academic Research Consortium[J].Eur Heart J, 2011,32(2): 205—217.
  • 10NICE. Transcatheter aortic valve implantation for aortic stenosis[EB/OL].(2012-03)[2014-06-20].htlp://guidance.nice.org.uMPG421/PublicInfo/pdf/English.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部